Latin America: How pharma can navigate a complex marketBureaucracy, political upheaval, and lack of regulations continue to make Latin America a difficult market for European and Share XLatin America: How pharma can navigate a complex markethttps://pharmaphorum.com/views-analysis-market-access/latin-america-how-pharma-can-navigate-a-complex-market/
FDA approves Alnylam’s ultra-rare disease drug OxlumoThe FDA has approved Alnylam’s gene silencing drug Oxlumo, the first treatment for primary hyperoxaluria type 1 (PH1), Share XFDA approves Alnylam’s ultra-rare disease drug Oxlumohttps://pharmaphorum.com/news/fda-approves-alynlams-ultra-rare-disease-drug-oxlumo/
Analysis casts doubt on increased use of telehealth after pandemicA team of US health analysts has cast doubt on whether the increased use in telehealth will continue Share XAnalysis casts doubt on increased use of telehealth after pandemichttps://pharmaphorum.com/news/analysis-casts-doubt-on-increased-use-of-telehealth-after-pandemic/
Roche takes on pricey rivals as FDA approves SMA drugRoche is hoping to undercut hugely expensive rivals after the FDA approved its oral spinal muscular atrophy (SMA) Share XRoche takes on pricey rivals as FDA approves SMA drughttps://pharmaphorum.com/news/roche-takes-on-pricey-rivals-as-fda-approves-sma-drug/
Windrose Consulting Group acquires ParioformaWindrose acquires Parioforma as part of growth strategy Share XWindrose Consulting Group acquires Parioformahttps://pharmaphorum.com/partner-content/windrose-consulting-group-acquires-parioforma/
Survey shows patients wait six times longer than EU neighbours for new drugsPatients in some European countries are waiting up to six times longer for access to medicines than their neighbours, Share XSurvey shows patients wait six times longer than EU neighbours for new drugshttps://pharmaphorum.com/news/survey-shows-patients-wait-six-times-longer-than-eu-neighbours-for-new-drugs/
The unprecedented challenge of pricing a coronavirus vaccineThe optimal pricing strategy for a new vaccine involves setting a fair and sustainable price that enables the Share XThe unprecedented challenge of pricing a coronavirus vaccinehttps://pharmaphorum.com/views-analysis-market-access/the-unprecedented-challenge-of-pricing-a-coronavirus-vaccine/
Gilead’s remdesivir could be $7.7bn blockbuster – analystAn influential analyst has upped his previously cautious assessment of the sales potential of Gilead’s COVID-19 drug remdesivir, saying Share XGilead’s remdesivir could be $7.7bn blockbuster – analysthttps://pharmaphorum.com/news/gileads-remdesivir-could-be-7-7bn-blockbuster-analyst/
‘Delusional’ Shkreli refused prison release to fight coronavirusMartin Shkreli, the pharma CEO once branded as America’s most hated man has been denied release from prison after a Share X‘Delusional’ Shkreli refused prison release to fight coronavirushttps://pharmaphorum.com/news/delusional-shkreli-refused-prison-release-to-fight-coronavirus/